Recent advances in the management of neovascular glaucoma

Seminars in Ophthalmology

Volumn 28, Issue 3, 2013, Pages 165-172

  Soohoo, Jeffrey R ^a   Seibold, Leonard K ^a   Kahook, Malik Y ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Anti VEGF; Glaucoma filtration surgery; Neovascular glaucoma

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; HUMAN IMMUNOGLOBULIN; PEGAPTANIB; PLATELET DERIVED GROWTH FACTOR; RANIBIZUMAB; SOMATOMEDIN C;

ADJUVANT THERAPY; ANGIOGENESIS; CELL PROLIFERATION; CENTRAL RETINA ARTERY OCCLUSION; FIBROBLAST; FOLLOW UP; GLAUCOMA DRAINAGE IMPLANT; HUMAN; INTRAOCULAR PRESSURE; IRIS; LASER COAGULATION; MONOTHERAPY; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; RETINA ISCHEMIA; REVIEW; TRABECULECTOMY;

ANGIOGENESIS INHIBITORS; FILTERING SURGERY; GLAUCOMA, NEOVASCULAR; HUMANS; IRIS; LASER THERAPY; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84878301954     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2012.730103     Document Type: Review

References (98)

1. Shazly TA, Latina MA. Neovascular glaucoma: Etiology, diagnosis and prognosis. Semin Ophthalmol 2009; 24(2): 113-121.
2. Kubota T, Tawara A, Hata Y, et al. Neovascular tissue in the intertrabecular spaces in eyes with neovascular glaucoma. Br J Ophthalmol 1996;80(8): 750-754. (Pubitemid 26334921)
3. Callahan MA. Letter: photocoagulation and rubeosis iridis. Am J Ophthalmol 1974;78(5): 873-874.
4. Krill AE, Archer D, Newell FW. Photocoagulation in complications secondary to branch vein occlusion. Arch Ophthalmol 1971;85(1): 48-60.
5. Laatikainen L. Preliminary report on effect of retinal panphotocoagulation on rubeosis iridis and neovascular glaucoma. Br J Ophthalmol 1977;61(4): 278-284. (Pubitemid 8074855)
6. Murphy RP, Egbert PR. Regression of iris neovascularization following panretinal photocoagulation. Arch Ophthalmol 1979;97(4): 700-702. (Pubitemid 9135279)
7. Wand M, Dueker DK, Aiello LM, Grant WM. Effects of panretinal photocoagulation on rubeosis iridis, angle neovascularization, and neovascular glaucoma. Am J Ophthalmol 1978;86(3): 332-339. (Pubitemid 9063022)
8. Michaelson IC. The mode of develoment of the vascular system of the retina with some observations of its significant in certain retinal diseases. Trans Ophthalmol Soc UK 1948;68: 137-180.
9. Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina 2007;27(7): 816-824. (Pubitemid 47479374)
10. Hilton GF. Panretinal cryotherapy for diabetic rubeosis. Arch Ophthalmol 1979;97(4): 776.
11. May DR, Bergstrom TJ, Parmet AJ, Schwartz JG. Treatment of neovascular glaucoma with transscleral panretinal cryotherapy. Ophthalmology 1980;87(11): 1106-1111. (Pubitemid 11232148)
12. Senger DR, Ledbetter SR, Claffey KP, et al. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 1996; 149(1): 293-305. (Pubitemid 26231000)
13. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-2342. (Pubitemid 38702844)
14. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6): 669-676. (Pubitemid 36749215)
15. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407(6801): 242-248.
16. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331(22): 1480-1487. (Pubitemid 24356306)
17. Tripathi RC, Borisuth NS, Li J, Tripathi BJ. Growth factors in the aqueous humor and their clinical significance. J Glaucoma 1994;3(3): 248-258. (Pubitemid 24267872)
18. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994;145(3): 574-584. (Pubitemid 24285965)
19. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia- associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114(1): 66-71. (Pubitemid 26026196)
20. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995;72(6): 638-645.
21. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118(4): 445-450. (Pubitemid 24307211)
22. Sivalingam A, Kenney J, Brown GC, et al. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1990; 108(6): 869-872. (Pubitemid 20193850)
23. Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulinlike growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease: studies in nondiabetic and diabetic subjects. J Clin Invest 1993;92(6): 2620-2625. (Pubitemid 24006525)
24. Glaser BM. Extracellular modulating factors and the control of intraocular neovascularization: An overview. Arch Ophthalmol 1988;106(5): 603-607.
25. Chakravarthy U, Adamis AP, Cunningham Jr ET, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113(9): 1508, e1501-1525.
26. Friberg TR, Tolentino M,Weber P, et al. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. Br J Ophthalmol 2010;94(12): 1611-1617.
27. Abraham P, Yue H, Wilson L. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150(3): 315-324, e311.
28. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14): 1432-1444. (Pubitemid 44511558)
29. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145(2): 239-248.
30. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14): 1419-1431. (Pubitemid 44511557)
31. Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother 2012;13(4): 585-591.
32. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36(4): 331-335. (Pubitemid 41073112)
33. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26(9): 999-1005. (Pubitemid 44973218)
34. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36(4): 336-339. (Pubitemid 41073113)
35. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26(3): 279-284. (Pubitemid 44318180)
36. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006;37(2): 144-146.
37. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113(10): 1695, e1691-1615.
38. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142(6): 1054-1056. (Pubitemid 44853889)
39. Grisanti S, Biester S, Peters S, et al. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006; 142(1): 158-160. (Pubitemid 43946796)
40. Mason 3rd JO, Albert Jr MA, Mays A, Vail R. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 2006;26(7): 839-841. (Pubitemid 44386115)
41. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006;142(1): 155-158.
42. Yazdani S, Hendi K, Pakravan M, et al. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma 2009;18(8): 632-637.
43. Grover S, Gupta S, Sharma R, et al. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol 2009;93(2): 273-274.
44. Sugimoto Y, Mochizuki H, Okumichi H, et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol 2010; 248(11): 1601-1609.
45. Saito Y, Higashide T, Takeda H, et al. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab. Am J Ophthalmol 2010;149(6): 964-972, e961.
46. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008;115(9): 1571-1580, e1571-1573.
47. Gheith ME, Siam GA, de Barros DS, et al. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 2007;23(5): 487-491. (Pubitemid 350202480)
48. Ehlers JP, Spirn MJ, Lam A, et al. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 2008;28(5): 696-702. (Pubitemid 351655121)
49. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003;48(3): 314-346. (Pubitemid 36549254)
50. The Fluorouracil Filtering Study Group. Five-year followup of the Fluorouracil Filtering Surgery Study. Am J Ophthalmol 1996;121(4): 349-366.
51. Cohen JS, Greff LJ, Novack GD, Wind BE. A placebocontrolled, double-masked evaluation of mitomycin C in combined glaucoma and cataract procedures. Ophthalmology 1996;103(11): 1934-1942. (Pubitemid 26403750)
52. Dietze PJ FR, Gross RL. Intraoperative application of 5-fluorouracil during trabeculectomy. Ophthalmic Surg 1992;23(10): 662-665.
53. Palanca-Capistrano AM, Hall J, Cantor LB, et al. Long-term outcomes of intraoperative 5-fluorouracil versus intraoperative mitomycin C in primary trabeculectomy surgery. Ophthalmology 2009;116(2): 185-190.
54. Zacharia PT, Deppermann SR, Schuman JS. Ocular hypotony after trabeculectomy with mitomycin C. Am J Ophthalmol 1993;116(3): 314-326. (Pubitemid 23263663)
55. Greenfield DS, Suner IJ, Miller MP, et al. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol 1996;114(8): 943-949. (Pubitemid 26271459)
56. Cornish KS, Ramamurthi S, Saidkasimova S, Ramaesh K. Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients. Eye (Lond) 2009;23(4): 979-981.
57. Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging 2006;37(2): 148-150.
58. Kahook MY. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. Am J Ophthalmol 2010;150(3): 399-403, e391.
59. Memarzadeh F, Varma R, Lin LT, et al. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 2009; 50(7): 3233-3237.
60. Kapetansky FM, Pappa KS, Krasnow MA. Suconjunctival injection(s) of bevacizumab for failing filtering blebs. Invest Ophthalmol Vis Sci 2007;E-Abstract 837.
61. Purcell JM, Teng CC, Tello C, et al. Effect of needle bleb revision with ranibizumab as a primary intervention in a failing bleb following trabeculectomy. Invest Ophthalmol Vis Sci 2008;E-Abstract 4165.
62. Grewal DS, Jain R, Kumar H, Grewal SP. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy: a pilot study. Ophthalmology 2008;115(12): 2141-2145, e2142.
63. How A, Chua JL, Charlton A, et al. Combined treatment with bevacizumab and 5-fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2010; 51(2): 928-932.
64. Jue A. Angiogenesis: Trabeculectomy and bevacizumab. Semin Ophthalmol 2009;24(2): 122-125.
65. Yoshida N, Hisatomi T, Ikeda Y, et al. Intravitreal bevacizumab treatment for neovascular glaucoma: Histopathological analysis of trabeculectomy specimens. Graefes Arch Clin Exp Ophthalmol 2011;249(10): 1547-1552.
66. Choi JY, Choi J, Kim YD. Subconjunctival bevacizumab as an adjunct to trabeculectomy in eyes with refractory glaucoma: A case series. Korean J Ophthalmol 2010;24(1): 47-52.
67. Fakhraie G, Katz LJ, Prasad A, et al. Surgical outcomes of intravitreal bevacizumab and guarded filtration surgery in neovascular glaucoma. J Glaucoma. Mar 2010;19(3): 212-218.
68. Gupta V, Jha R, Rao A, et al. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. Eur J Ophthalmol 2009;19(3): 435-441.
69. Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther 2008;25(5): 438-443.
70. Takihara Y, Inatani M, Kawaji T, et al. Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma. J Glaucoma 2011;20(3): 196-201.
71. Bochmann F, Kaufmann C, Becht CN, et al. ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma: Study protocol. BMC Ophthalmol 2011;11: 1.
72. Kim YG, Hong S, Lee CS, et al. Level of vascular endothelial growth factor in aqueous humor and surgical results of ahmed glaucoma valve implantation in patients with neovascular glaucoma. J Glaucoma 2009; 18(6): 443-447.
73. Sothornwit N. Intravitreal bevacizumab for ahmed glaucoma valve implantation in neovascular glaucoma: a case report. J Med Assoc Thai 2008;91(Suppl 1):S162-165.
74. Altintas AG, Arifoglu HB, Tutar E, et al. Effect on anterior chamber bevacizumab injection combined with seton implantation in treatment of rubeosis iridis in neovascular glaucoma. Cutan Ocul Toxicol 2012;31(2): 124-127.
75. Guerriero E, Yu JY, Kahook MY, et al. Morphologic evaluation of bevacizumab (Avastin) treated corneal stromal fibroblasts. Invest Ophthalmol Vis Sci 2006;EAbstract 1642.
76. Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007; 26(8): 977-982. (Pubitemid 47329805)
77. Yu JY, Kahook MY, Noecker RJ, et al. The effect of avastin on conjunctival fibroblasts. American Glaucoma Society, San Francisco, California. 2007;2 March 2007.
78. O'Neill EC, Qin Q, Van Bergen NJ, et al. Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci 2010;51(12): 6524-6532.
79. Vasuvedan S. Anti-VEGF anti-fibrosis: A comparison of ranibizumab and bevacizumab in vitro. Invest Ophthalmol Vis Sci 2009;E-Abstract 466.
80. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006;26(5): 512-518. (Pubitemid 44620391)
81. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 2006;90(10): 1316-1321. (Pubitemid 44621499)
82. Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma 2010;19(7): 437-441.
83. Higashide T, Murotani E, Saito Y, et al. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol 2012;250(4): 603-610.
84. Mete A, Saygili O, Bayram M, Bekir N. Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular agerelated macular degeneration. J Clin Ultrasound 2010; 38(2): 66-70.
85. Toklu Y, Cakmak HB, Raza S, et al. Short-term effects of intravitreal bevacizumab (Avastin(R)) on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration. Acta Ophthalmol 2011;89(1):e41-45.
86. Sacu S, Pemp B, Weigert G, et al. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti- VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Vis Sci 2011;52(6): 3046-3050.
87. Sagong M, Kim J, Chang W. Intravitreal bevacizumab for the treatment of neovascular glaucoma associated with central retinal artery occlusion. Korean J Ophthalmol 2009; 23(3): 215-218.
88. von Hanno T, Kinge B, Fossen K. Retinal artery occlusion following intravitreal anti-VEGF therapy. Acta Ophthalmol 2010;88(2): 263-266.
89. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011; 95(8): 1111-1114.
90. Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009;40(3): 293-295.
91. Mathalone N, Arodi-Golan A, Sar S, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012;250(10): 1435-1440.
92. Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 2011; 31(6): 1028-1035.
93. Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye (Lond) 2007;21(12): 1541.
94. Tolentino M. Systemic and ocular safety of intravitreal anti- VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56(2): 95-113.
95. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364(20): 1897-1908.
96. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular agerelated macular degeneration: two-year results. Ophthalmology 2012;119(7): 1388-1398.
97. Arevalo JF, Maia M, Flynn Jr HW, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92(2): 213-216. (Pubitemid 351224097)
98. Moradian S, Ahmadieh H, Malihi M, et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008; 246(12): 1699-1705.